Follow ImmunityBio, Inc.. Every new filing, FDA action, and trial change, in your feed and a morning email, each linked to its source.
6 Stories in coverage 5 Programs 123 recruiting Registered trials 10-Q Nov 16 Latest SEC filing Nov 10 Latest story
Timeline 6 Pipeline 5 Trials 12
All6 Regulatory3 Trials and readouts3 Filings and people2
Pipeline by stage
Phase 3 1 Phase 2 1 Phase 1 3
Details
Headquarters San Diego, CA Incorporated Delaware Industry Biological Products, (No Diagnostic Substances) Formerly NantKwest, Inc. (to 2021); Conkwest, Inc. (to 2015); ZelleRx Corp (to 2009) Also known as Conkwest, Inc., IBRX, NantKwest, Inc., ZelleRx Corp How the company describes itself ImmunityBio develops immunotherapies including an IL-15 superagonist, adenovirus-vectored vaccines, and allogeneic and autologous NK-cell therapies for cancer and infectious diseases. The company's Cancer BioShield platform targets natural killer cells, cytotoxic T cells, and memory T cells. source